Novel Microdevices, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Novel Microdevices, Inc. - overview
Established
2016
Location
Baltimore, MD, US
Primary Industry
Medical Devices & Equipment
About
Based in Maryland, US, and founded in 2016 by Andrea Pais (CEO) and Rohan Pais, Novel Microdevices operates as a developer and manufacturer of medical devices intended to facilitate molecular diagnostics. In February 2025, Novel Microdevices, Inc. raised USD 500,000 million in venture funding from new investor Maryland Technology Development Corporation, with participation from returning investor TEDCO. The firm develops and commercializes its proprietary Point-of-Care (POC) rapid molecular diagnostics system called Novel Dx that implements polymerase chain reaction (PCR) technology on a disposable cartridge to diagnose the genetic sequence of cells to identify the disease and the presence of genetic mutations that makes bacteria resistant to antibiotics.
The firm diagnoses sexually transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae using vaginal swabs or urine samples. The company will use the February 2025 funding to support the development and distribution of its product in the healthcare industry.
Current Investors
The National Institutes of Health, Maryland Technology Development Corporation, TEDCO
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Medical Devices & Equipment, Diagnostic Equipment
Website
www.noveldx.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.